Our Expert Network

31. Rethinking The Oligonucleotide Backbone: Why RNA Therapeutics May Need A New Molecular Design Framework 6/24/2026

    New backbone chemistries could unlock greater control over delivery, specificity, and safety, expanding the molecular design space for RNA medicines.

32. RNA Platforms: What Transfers And What Breaks 6/23/2026

    A practical framework for distinguishing reusable RNA platform knowledge from biology-specific unknowns as therapeutics expand into new tissues and indications.

33. The Hidden Language Of RNA: How lncRNA-Splicing Networks Are Redefining The Future Of Therapeutics 6/19/2026

    Long non-coding RNAs and splicing networks are emerging as master regulators of cellular identity, opening new therapeutic opportunities beyond proteins.

34. RNA-Binding Proteins As Architects Of Post-Transcriptional Control In Disease Biology 6/18/2026

    RNA-binding proteins orchestrate splicing, stability, localization, and translation, emerging as powerful regulators and therapeutic targets in disease.

35. Beyond The Liver: How Machine Learning-Optimized LNPs Are Expanding RNA Delivery Into Adipose Tissue 6/8/2026

    Machine learning-guided LNP design is enabling targeted RNA delivery to adipose tissue, opening new possibilities for obesity, metabolic disease, and beyond.

36. Structure-Guided siRNA Design: How Chemistry, Context, And Constraint Are Shaping The Next Phase Of RNAi Therapeutics 6/8/2026

    As siRNA design matures, the next breakthroughs will depend on balancing chemical optimization, delivery challenges, and expanding beyond established design rules.

37. Scaling RNA Therapeutics: Purification, LNP Formulation, And GMP Manufacturing (Pt. 2) 6/4/2026

    Part 2 explores the downstream technologies that turn RNA into a therapeutic product, from impurity removal and LNP formulation to GMP infrastructure and scalable manufacturing.

38. From Exosomes To Nanodrugs: Advancing Therapeutic Delivery For CNS Repair 6/1/2026

    Exosomes are biological vesicles used for cellular communication that can overcome CNS barriers, delivering therapeutic cargo for CNS and optic nerve injuries.

39. Why RNAi-Based Oncology Must Move Beyond Single-Target Thinking 5/29/2026

    RNAi therapeutics may help oncology move beyond single-target drugs by disrupting adaptive tumor survival networks driving resistance in solid tumors.

40. What Makes An RNA Platform Investable? Lessons From The Last Wave Of Biotech Financing 5/28/2026

    RNA investing has shifted from hype to scalability, forcing companies to prove manufacturability, delivery strength, and platform-wide value.